Find Clinical Trials

Inclusion Criteria: * High-risk breast cancer patients with a family history of breast cancer or genetic predispositions (e.g., BRCA mutations). * Patients aged 30-65 years. * Patients willing to undergo breast MRI screening for DCIS detection. Exclusion Criteria: * Patients with contraindications to MRI imaging (e.g., pacemakers, claustrophobia). * Patients with a history of prior breast surgery or interventions that may interfere with imaging interpretation.

Inclusion Criteria: 1. Must be competent and able to comprehend, sign, and date an Institutional Review Board (IRB) approved ICF before performance of any study-specific procedures or tests. 2. Men or women ≥18 years old. 3. Pathologically documented breast cancer that is unresectable or metastatic. 4. 4.Tumor biopsies have always shown HER2-IHC 0 (\<10% membrane staining, including 0 null and 0 ultralow) in all prior biopsies and never previously HER2-positive (IHC 3+ or ISH+) or HER2-low (1+, or 2+ ISH-) on prior pathology testing according to American Society of Clinical Oncology College of American Pathologists (ASCO-CAP) guidelines. 5. Either HR-positive or HR-negative status of the tumor per ASCO-CAP guidelines are allowed. 6. Patients with HR-positive disease must have progressed or be intolerant to CDK 4/6 inhibitors plus endocrine therapy, and patients with HR-negative disease must have received 1 line of therapy in the metastatic setting (progression on or within 6 months of neoadjuvant or adjuvant therapy will be accounted for as 1 line of prior therapy). There is no limit on number of subsequent lines of therapy for study entry. . 7. Patients must have never been previously treated with any anti-HER2 therapy, including prior trastuzumab deruxtecan, other HER2-directed ADCs, HER2 antibodies or HER2 tyrosine kinase inhibitors 8. Clinical or radiologic progression (during or after most recent treatment) or intolerance to therapy prior to enrollment in this trial 9. Adequate archival tumor sample \<3 years-old available for assessment of HER2 status by IHC and by HS-HER2 quantitative assay. If archival tissue is not available or inadequate for assessment (e.g. decalcified bone, cytology, or other), a newly obtained biopsy from a metastatic site (or breast tissue if locally advanced/unresectable disease as the only site of advanced disease) is required on enrolment. 10. Presence of at least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. 11. ECOG PS ≤ 2. 12. Left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to C1D1. 13. Adequate bone marrow function (Table 1) within 28 days before C1D1, defined as: 1. Platelet count \>≥100,000/mm3 (Platelet transfusion is not allowed within 1 week prior to Screening assessment). 2. Hemoglobin level ≥9.0 g/dL (red blood cell transfusion is not allowed within 1 week prior to Screening assessment). 3. Absolute neutrophil count ≥1500/mm3 (granulocyte colony-stimulating factor administration is not allowed within 1 week prior to Screening assessment). 14. Adequate renal function (Table 1) within 28 days before C1D1, defined as: a. Creatinine clearance ≥30 mL/min, as calculated using the Cockcroft-Gault Equation. 15. Adequate hepatic function (Table 1) within 28 days before C1D1, defined as: 1. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3×ULN (\< 5×ULN in participants with liver metastases). 2. Total bilirubin ≤1.5 × ULN if no liver metastases or \<3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline. 16. Adequate blood clotting function( defined below) within 28 days before C1D1, defined as International normalized ratio or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time ≤ 1.5 × ULN. 1. Platelet function greater than or equal to 100000/mm3 (Platelet transfusion is not allowed within 1 week prior to C1D1). 2. Hemoglobin greater than or equal to 9.0 g/dL NOTE: Participants requiring ongoing transfusions or growth factor support to maintain haemoglobin ≥9.0 g/dL are not eligible. Red blood cell transfusion is not allowed within 1 week prior to C1D1. 3. Absolute neutrophil count greater than or equal to 1500/mm3. (granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1). 4. Alanine aminotransferase and aspartate aminotransferase less than or equal to 3×ULN (\< 5×ULN in participants with liver metastases). 5. Total bilirubin less than or equal to 1.5×ULN if no liver metastases or \< 3×ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline. 6. Serum albumin greater than or equal to 2.5 g/dL 7. Creatine clearance greater than or equal to 30 mL/min as determined by Cockcroft Gault (using actual body weight). 8. International normalised ratio or Prothrombin time and either partial thromboplastin or activated partial thromboplastin time less than or equal to 1.5 x upper limit of normal 17. Adequate treatment washout period before C1D1, defined below: 1. Major surgery minimum washout period of greater than or equal to 4 weeks 2. Radiation therapy including palliative stereotactic radiation therapy to chest minimum washout period greater than or equal to 4 weeks 3. Palliative stereotactic radiation therapy to other anatomic areas including whole brain radiation minimum wash out period of greater than or equal 2 weeks 4. Anti-Cancer chemotherapy \[Immunotherapy (non-antibody based therapy)\], hormonal therapy, antibody-based therapy, or retinoid therapy minimum washout period greater than or equal to 3 weeks 5. Anti-Cancer chemotherapy \[Immunotherapy (non-antibody based therapy)\], hormonal therapy, antibody-based therapy, or retinoid therapy minimum washout period greater than or equal 3 weeks 6. Targeted agents and small molecules minimum washout period greater than or equal 2 weeks or 5 half-lives, whichever is longer 7. Cell-free and Concentrated Ascites Reinfusion Therapy (CART), peritoneal shunt or drainage of pleural effusion, ascites or pericardial effusion minimum washout period greater than or equal to 2 weeks prior to screening assessment 8. Any monoclonal antibody treatment minimum washout period greater than or equal to 3 elimination half-lives of the inhibitor/antibody 18. Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of T-DXd. Women of childbearing potential are defined as those who are not surgically sterile (i.e. underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. 19. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 3 from the time of screening (those using hormonal methods must have been stable on their chosen form of contraception for 3 months prior to study entry) and must agree to continue using such precautions for 7 months after the last dose of T-DXd. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of T-DXd. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. 20. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom from screening to 4 months after the final dose of T-DXd. Complete heterosexual abstinence for the duration of the study and drug washout period

Inclusion Criteria: * Adults aged 18 years or above * Diagnosis of type 2 diabetes at least 6 months * CKD (eGFR by CKD-EPI 25-90 ml/min/1.73m2 with uACR 30 to \<300 mg/g) and/or those with severely elevated albuminuria (uACR 30-5000 mg/g) and eGFR \> 60 ml/min/1.73m2. * Patients should have a serum potassium \<4.8 mmol/l at screening * On SGLT2i (dapagliflozin or empaglifozin) at screening at stable doses for at least 4 weeks. * On ACEi or ARB at maximum tolerated dose per manufacturer's label that did not cause unacceptable side effects * In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a suitable study candidate. Exclusion Criteria: * Type 1 diabetes * Allergy, contraindications or intolerance to ACEi/ARB * Contraindications or intolerance to mineralocorticoid receptor antagonists * Allergy, contraindications to SGLT2is * Currently pregnant or planning pregnancy * HbA1c \>9% at enrolment * Uncontrolled hypertension SBP \> 160mmHg or hypotension \<90 mmHg at enrolment * Concomitant therapy with eplenerone, spironolactone that cannot be discontinued. * History of stroke or worsening heart failure in the past 6 months prior to screening * Diabetic ketoacidosis, hyperosmolar hyperglycaemic state or myocardial infarction in the six months prior to screening * Patients on renal replacement therapy or likely require kidney transplant or dialysis during the study period * On concomitant strong CYP3A4 inhibitors that cannot be discontinued * Adrenal insufficiency * Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection. * An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).

Inclusion Criteria: 1. Provided written informed consent. 2. Patients aged ≥ 18 years. 3. \- For basket 1 and 2: HCC or ICC histologically proven: newly diagnosed patients or patients with suspected refractory, residual, or recurrent disease. \- For basket 3: Progressive GEP-NENs with low or heterogeneous expression of SSTR2 or progressive pancreatic NENs which previously received at least two systemic treatments (excluding SSA) or pancreatic NENs with germline or somatic VHL mutation or G3 GEP-NENs . 4. Presence of at least one morphological evaluable lesion according to RECIST 1.1 using contrast CT/MRI. 5. Patients must have an ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 2. 6. For cirrhotic patients: Child-Pugh ≤ B7. 7. Patient affiliated to or beneficiary of the National Health Service. Exclusion Criteria: 1. Known hypersensitivity to zirconium-89, to any excipient or derivative or to radiographic contrast agents. 2. Chemotherapy, extensive external beam radiation, immunotherapy, targeted therapy, or angiogenesis inhibitors within 2 weeks prior to 89Zr-TLX250 administration. 3. Radionucleide targeted therapy prior to inclusion within 3 months prior to inclusion. 4. Radioembolization within 3 months prior to inclusion. 5. Uncontrolled brain or spinal cord metastasis. 6. Cardiac disease with New York Heart Association classification of III or IV. 7. Life expectancy shorter than 4 months. 8. Any major surgery within 4 weeks before enrollment. 9. Any uncontrolled significant medical, psychiatric or surgical condition (active infection (subjects with known human immunodeficiency virus (HIV) positive)), unstable angina pectoris, cardiac arrhythmia, poorly controlled hypertension, poorly controlled diabetes mellitus (glycated haemoglobin (HbA1c) ≥9%), uncontrolled congestive heart disease, etc.) or laboratory findings that, in the opinion of the investigator, might jeopardise the subject's safety or that would limit compliance with the objectives and assessments of the study. 10. Other known malignancies (except for fully-resected non-melanoma skin cancer or cervical cancer in situ) unless definitively treated and proven no evidence of recurrence for 2 years. 11. Women who are pregnant or breastfeeding. A serum pregnancy test will be performed at the start of the study for all female subjects of childbearing potential. 12. Patient under guardianship or trusteeship. 13. Patient under judicial protection.

Inclusion Criteria: * women who had preeclampsia and women who did not have preeclampsia * 12 weeks to 5 years postpartum * 18-45 years old Exclusion Criteria: * history of hypertension or metabolic disease before pregnancy * history of gestational diabetes * history of gestational hypertension without preeclampsia * skin diseases * current tobacco use * current antihypertensive medication * statin or other cholesterol-lowering medication * currently pregnant * body mass index less than 18.5 kg/m2 * allergy to materials used during the experiment.(e.g. latex), * known allergy to study drugs or salt-supplement

Inclusion Criteria: \- Voluntarily agree to participate in this study. Age: 18-80 years, regardless of gender. Pathological and imaging diagnosis of advanced or recurrent malignant tumors. The patient must have previously received systemic standard treatment that has failed or led to disease progression, with no effective first-line treatment options available for advanced tumors (effective treatment options refer to the latest clinical guidelines published by the "Chinese Society of Clinical Oncology"). Alternatively, the patient may have undergone standard surgical treatment for tumor relapse prevention. At least one measurable lesion on imaging (excluding patients who have undergone surgical treatment). Expected survival ≥ 6 months. ECOG (Eastern Cooperative Oncology Group) performance status score of 0-1. No infectious diseases: HIV antibody negative. Normal hematological function: White blood cells ≥ 3000 cells/µL, hemoglobin ≥ 9 g/dL, platelets ≥ 75,000 cells/µL, absolute neutrophil count \> 1000 cells/mm³. Normal renal function: Serum creatinine (Cr) ≤ ULN × 1.5. Normal liver function: Serum ALT/AST levels less than three times the upper limit of normal. The patient must be willing to sign an informed consent form and able to comply with the treatment plan. The patient must undergo tumor resection or biopsy (for vaccine preparation) and peripheral blood collection (for efficacy and prognosis evaluation). Exclusion Criteria: \- Patients who do not have enough tumor resected or puncture tissue for vaccine production. Patients who have failed third-line therapy, and whose tumor location or type is not suitable for radiotherapy (as evaluated by the expert group). Patients whose tumor tissue preparation for the vaccine does not meet the efficacy assessment criteria before enrollment (individualized FAST vaccine Elispot test, see Appendix 4 for specific testing protocol). Patients with a history of bone marrow or stem cell transplantation. Patients currently participating in other therapeutic clinical trials; Traditional Chinese medicine clinical trials. Patients with active bacterial or fungal infections as per NCI-CTC (National Cancer Institute Common Terminology Criteria for Adverse Events) CTCAE 5.0. Patients infected with HIV (Human Immunodeficiency Virus), HCV (Hepatitis C Virus), HBV (Hepatitis B Virus), severe asthma, autoimmune diseases, immunodeficiency, or those undergoing immunosuppressive therapy. Patients with herpesvirus infection (except those whose lesions have scabbed for more than 4 weeks). Patients with respiratory viral infections (except those who have been cured for more than 4 weeks). Patients with severe coronary artery or cerebrovascular diseases, or other diseases that the investigator considers should be excluded. Patients with clinical, psychological, or social factors that affect their ability to provide informed consent for the study. Patients with a history of autoimmune diseases, such as but not limited to inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Patients with autoimmune-related thyroid diseases and vitiligo are allowed. Patients with severe chronic or acute comorbidities, such as heart disease (NYHA Class III or IV), liver disease, or other diseases that the principal investigator considers to pose unnecessary high risk in relation to the study drug treatment. Patients who have a second malignant tumor at the same time (or within the past 5 years), except for melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other treated carcinoma in situ. Patients with active acute or chronic infections, including urinary tract infections, HIV (as confirmed by ELISA and Western Blot). HIV-infected individuals may be excluded because immunosuppression could prevent them from responding to the vaccine; chronic hepatitis patients may be excluded due to concerns that vaccination could exacerbate their hepatitis. Patients with a history of drug or peptide allergies, or allergies to other potential immunotherapies. Patients undergoing chronic steroid treatment (or other immunosuppressive agents, such as azathioprine or cyclosporine A) will be excluded due to potential immunosuppression. Patients must stop any steroid treatment 6 weeks prior to enrollment (except for drugs used for chemotherapy, contrast-enhanced imaging, or acute treatment of complications such as gout attacks \<5 days). Patients with acute or chronic skin diseases will be excluded, as these conditions could affect the injection into the skin of the limbs or the subsequent evaluation of potential skin reactions. Patients without legal capacity.

Inclusion Criteria: * Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic. Exclusion Criteria: * Adults lacking capacity to consent

Inclusion Criteria: 1. Histopathologically proven left sided invasive breast cancer patients who underwent modified radical mastectomy. 2. Post mastectomy patients for whom radiotherapy including supraclavicular irradiation is indicated. 3. Patients having ECOG performance status up to 1. Exclusion Criteria: 1. Left sided breast cancer patient underwent BCS. 2. Patient received any chemotherapy other than Doxorubicin, Cyclophosphamide and taxane (Paclitaxel/ Docetaxel) in any settings (neoadjuvant or adjuvant). 3. Patients who have comorbidities that would hinder DIBH (extreme obesity, mental disorder, hypoacusis etc.). 4. Known case of patients with respiratory diseases. 5. Known case of patients with ischemic heart diseases. 6. Patients with previous history of radiotherapy to chest. 7. Male breast cancer patients. 8. Bilateral breast cancer patients. 9. Pregnant or lactating women. 10. Age ˂ 18 years.

Inclusion Criteria: * Female patients with early stage breast cancer who will undergo breast-conserving surgery Exclusion Criteria: * Patients receiving neoadjuvant radiotherapy and chemotherapy * Patients who will undergo axillary lymph dissection and total mastectomy * Asa 4-5 patients * Patients without voluntary consent * Patients with previous surgery or vertebrobasilar insufficiency * Patients with Carotis stenosis * Patients with a visual analog scale above 4 in the postoperative recovery unit * Patients in whom cerebral oxygenation decreased by 15% from the beginning in cerebral oximetry monitoring during the perioperative period * Patients with bleeding that disrupts hemodynamics during follow-up and bleeding greater than 20% of body volume * Patients with postoperative intensive care unit follow-up * Patients with a decrease of more than 20% from the baseline systolic value (based on ward monitoring) during follow-up * Patients with intraoperative ventilation failure, patients with hypercarbia, hypocarbia * Patients whose Patient State Index value falls below 25, which is sufficient for the depth of anesthesia, during anesthesia induction or maintenance. * Patients with known neurological, psychiatric, unstable cardiovascular, renal or hepatic system disease * Patients with Uncontrolled Hypertension * Patients with greater than 1st degree heart block * Patients allergic to α2 adrenergic receptor agonist * Patients who cannot speak and do not know Turkish * Alcohol and substance addicted patients * Patients who have used opioids in the last 24 hours * Patients who developed sepsis during postoperative follow-up * Patients with a history of recurrent surgery

Inclusion Criteria: 1. Age ranging from 18 to 75 years 2. Pathologically confirmed invasive breast cancer 3. Receiving preoperative chemotherapy (Each molecular subtype corresponds to unanimous regimen) 4. cT1-3N0-3M0 5. Unilateral breast tumor 6. Eastern Cooperative Oncology Group score 0-1 7. Left Ventricular Ejection Fraction (LVEF) ≥50% 8. Leukocytes ≥ 3.0×109/L, Absolute neutrophil count ≥ 1.5×109/L, Platelets ≥ 100×109/L, Hemoglobin ≥ 90g/L, Creatinine \<1.5 × institutional ULN, Total bilirubin ≤ 2.0 × institutional ULN. Exclusion Criteria: 1. Diffusely disseminated malignant calcification foci 2. Not applicable for BCS after neoadjuvant therapy 3. Pregnancy or breastfeeding 4. Additional malignancy 5. Severe cardiopulmonary, liver or kidney dysfunction or other systemic diseases (such as uncontrolled chronic heart failure, critical hypertension or diabetes with poor blood glucose control).

Inclusion Criteria: * 1\. Female patients aged 18-70 years. 2. ECOG performance status of 0-2. 3. Newly diagnosed invasive breast cancer, underwent breast-conserving surgery plus axillary lymph node dissection, with positive axillary lymph nodes (ypN+) and negative surgical margins. 4\. No distant metastasis. 5. Capable of tolerating radiotherapy. 6. For ER/PR-positive patients, willing to receive anticipated 5 years of endocrine therapy. 7\. For HER2-positive patients, willing to receive anticipated 1 year of anti-HER2 targeted therapy. 8\. For patients requiring neoadjuvant/adjuvant chemotherapy, must have completed chemotherapy. 9\. Left ventricular ejection fraction (LVEF) measured by echocardiography is 50%. 10\. Must undergo adjuvant IMRT (Intensity-Modulated Radiation Therapy). 11. Capable of tolerating lying still on the treatment accelerator bed for 30 minutes to complete All-In-One radiotherapy. 12\. Have follow-up conditions and are willing to adhere to follow-up. 13. Signed an informed consent form. Exclusion Criteria: * 1\. Synchronous bilateral breast cancer; sentinel lymph node biopsy of the axilla was performed without axillary lymph node dissection. 2\. Stage I breast reconstruction surgery or expander implantation surgery on the affected side chest wall. 3\. The purpose of radiotherapy is palliative. 4. Myocardial infarction within the last 3 months or uncorrected unstable arrhythmia or uncorrected unstable angina. 5\. History of chest wall or supraclavicular radiotherapy in the past; past or concurrent second primary malignant tumors (except for non-melanoma skin cancer, papillary/follicular thyroid carcinoma, and carcinoma in situ of the cervix). 6\. All-in-one one-stop radiotherapy has not been completed.

Inclusion Criteria: * Pregnant women ≥ 18 years old * High risk of PE (≥ 1 high-risk factor, or ≥3 moderate risk factors according to the Swedish Society of Obstetrics and Gynecology (SFOG) 2019 guidelines); or low risk of PE (no high-risk factors, or \&lt;3 moderate risk factors): * High risk factors are: * Auto-immune diseases such as SLE or anti-phospholipid syndrome * Previous preeclampsia or eclampsia * Previous hypertension of pregnancy with preterm birth before gestational week 34, growth restriction, intrauterine fetal death or ablatio * Type 1 or 2 diabetes * Duplex (or triplex) pregnancy * Kidney disease * Chronic hypertension * IVF with egg donation * Moderate risk factors are: * Nulliparity * Heredity for preeclampsia (at least one of mother, maternal grandmother, or sister) * BMI\&gt;30 * Age\&gt;40 * Pregnancy interval \&gt;10 years * Systolic blood pressure \&gt;130 mmHg or diastolic blood pressure \&gt; 80 mmHg at admission in antenatal maternity care * African descent * Verified obstructive sleep apnea * Ability to give written informed consent Exclusion Criteria: * Enrollment in another clinical study * Use of other probiotic supplements in the last 2 weeks before baseline, or during the course of the study * Use of antibiotics in the last 6 weeks * Current treatment with metformin, progesterone, or regular medical treatment which may impact study aim (e.g. laxatives) * Immunosuppression * Diabetes mellitus (type I and type II) * Inflammatory bowel disease * Celiac disease * Bad obstetric history * Other serious conditions that might affect gut flora or capability of the subject to participate * Language difficulties or difficulties understanding informed consent

Inclusion Criteria: * Meets the diagnostic criteria for asthma or COPD. * Age of athma range from 12 years to 80 years.Age of COPD range from 18 years to 80 years. * The investigators agreed to participate in this clinical study by voluntarily signing an informed consent form. Exclusion Criteria: * Patients with respiratory diseases such as interstitial lung disease, lung malignant tumor, lung infectious diseases, pneumothorax, pleural effusion, etc., which affect the syndrome differentiation. * Patients with combining severe cardiovascular and cerebrovascular diseases, severe liver and kidney diseases, severe hematological malignancies, etc., affecting syndrome differentiation. * Patients with delirium, dementia, various mental illnesses.

Inclusion Criteria: * 1\. Able to give voluntary informed consent; 2. Satisfy criteria for Diagnostic and Statistical Manual 5th edition (DSM-V) for Major Depression Disorder (MDD) 3. Currently in a depressive episode (MDE); 4. Montgomery and Asberg Depression Rating Scale (MADRS) score \>21 but \<32(moderate to severe depression)11; 3. Psychotropic medication-free \> 2weeks and if on fluoxetine then for \>5 weeks at time of inclusion in the study(no taper or medication washout will be done for the purpose of the study). 6. Satisfy criteria to undergo an MRI scan based on MRI screening questionnaire; 7) able to be managed as outpatients during the study as ascertained by Clinical Global Severity Scale \< 5 (i.e., moderately ill) and no suicidal/homicidal intent or behavior or gross disability; and 8) no contraindication to KET treatment such as KET allergy or uncontrolled hypertension. Exclusion Criteria: * 1\. Meeting DSM-5 criteria for (hypo)mania, bipolar disorder, schizophrenia, schizophreniform disorder, schizoaffective disorder, intellectual disability, or pervasive developmental disorder; 2. History of receiving electroconvulsive therapy in the past 1 year (due to possible effects on brain morphology); 3. Meeting DSM-5 criteria for moderate or severe substance/alcohol use within the past 6 months excluding caffeine or nicotine. The criteria will be evaluated by interview and urinary toxicology screening. The typical weekly use of caffeine, nicotine and alcohol will be recorded; 4. No serious medical or neurological illness, including previously known HIV positive status (due to possible CNS involvement) as assessed by history, physical examination and laboratory examination including EKG, CBC and blood chemistry; 5. Current pregnancy or breast feeding; 6. Metallic implants or contraindication to MRI.

Inclusion Criteria: * Aged between 18 and 44 years old * With at least one risk factor for diabetes Exclusion Criteria: * Known history of Diabetes * With conditions considered not suitable by the project team (including illiteracy) The risk factors for diabetes include central or general obesity, family history of diabetes, smoking history, history of hypertension/ high blood glucose level/ abnormal lipid level/ vascular disease/ fatty liver, history of gestational diabetes/ polycystic ovary syndrome/ delivery of baby≥ 4kg (for women only), and less than 150mins of physical activity every week.

Inclusion Criteria: 1. Signed the informed consent form 2. Age ≥18 years. 3. Weighs more than 40 kg. For doses \<0.3 mg/kg, subject must weigh ≥70 kg. 4. Has a life expectancy of ≥3 months. 5. Has documented locally advanced or metastatic HER2-positive solid tumor(s) (IHC 1+ to 3+ or in situ hybridization \[ISH\] positive) or HER2-mutant tumor specimen not amenable to curative surgery or radiation and has received at least 1 line of standard therapy in the advanced/metastatic setting, or for which no standard treatment is available, including: 1. Cohort 1: HER2-positive breast cancer (BC); 2. Cohort 2: HER2-positive gastric/gastroesophageal junction cancer (GC/GEJ); 3. Cohort 3: HER2-positive or HER2-mutant non-small cell lung cancer (NSCLC); 4. Cohort 4: HER2-positive endometrial cancer (EC); 5. Cohort 5: HER2-positive ovarian cancer (OC), including fallopian tube cancer and primary peritoneal cancer; 6. Cohort 6: HER2-positive urothelial cancers (UC); 7. Cohort 7: Other HER2-positive solid tumors as approved by the medical monitor. Note: For indications in which a HER2-directed therapy is approved, the approved treatment is recommended although not mandated, at the discretion of the investigator. 6. Agree to provide most recent existing tumor samples (FFPE tissue block or slides) from primary or metastatic sites for tissue-based IHC staining to centrally determine HER2 expression: 1. In dose escalation and dose finding: archival tissue or fresh biopsy. If no archival tissue is available or it is not possible to obtain a fresh tissue biopsy, medical monitor approval is required; 2. In dose expansion: an FFPE block or slides from fresh biopsy or the most recent archival tissue is required. 7. Has at least one measurable lesion based on RECIST (Response Evaluation Criteria in Solid Tumors) V1.1. 8. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1. 9. Toxicity of previous antitumor therapy has returned to Grade ≤1 as defined by NCI CTCAE V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2. 10. No serious cardiac dysfunction and left ventricular ejection fraction ≥50%. 11. Has adequate organ function before enrollment, defined as: 1. Marrow function: Absolute neutrophil count (ANC) ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin (Hb) ≥9.0 g/dL (blood transfusion, platelet transfusion, erythropoietin, platelet-stimulating agents, and G-CSF use are not allowed 1 week prior to screening); 2. Hepatic function: Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for subjects with Gilbert's syndrome or liver metastasis at baseline), AST and ALT without liver metastasis ≤3.0×ULN, AST and ALT with liver metastasis ≤5.0×ULN; 3. Renal function: Creatinine (Cr) clearance ≥60 mL/minute (Cockcroft-Gault equation). 12. Coagulation parameters: International normalized ratio (INR) ≤1.5×ULN, and activated partial thromboplastin time (aPTT) ≤1.5×ULN, unless receiving anticoagulation therapy with PT and aPTT levels within the intended therapeutic range. 13. Urine protein ≤2+ or ≤1000 mg/24 hours. 14. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended. 15. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating. Female subjects are considered WOCBP unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \>45 years old in the absence of other biological or physiological causes. In addition, females \<55 years old must have a serum follicle stimulating hormone (FSH) level \>40 mIU/mL to confirm menopause. Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff. Exclusion Criteria: Subjects who meet any of the following criteria will not be eligible for participation in this study: 1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other antitumor therapy within 4 weeks or 5 half-lives (whichever is shorter) prior to the first administration; major surgery within 4 weeks prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration. 2. Concomitant use of strong inhibitors and inducers of any CYP3A4 enzyme or P-gp transporter system within 2 weeks or 5 half-lives (whichever is longer) prior to the first administration and throughout all parts of the study. 3. History of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ Grade 2 heart failure at any time, or history of myocardial infarction or unstable angina pectoris within 6 months before enrollment. 4. Prolonged QT interval (QTcF \>470 msec), complete left bundle branch block, Grade 3 atrioventricular block, or a history of additional risk factors for torsades de pointes (TdP; eg, heart failure as defined in Exclusion Criterion 3, chronic or recurrent hypokalemia that requires medical intervention, congenital long QT syndrome, family history of long QT syndrome) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP. 5. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for type 1 diabetes, hypothyroidism that can be controlled by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis). 6. Other prior malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with a disease-free interval of at least 3 years prior to screening. 7. Poorly controlled hypertension by two types of antihypertensive drugs (systolic blood pressure \>150 mmHg or diastolic blood pressure \>100 mmHg). 8. Advanced or clinically significant lung diseases, such as poorly controlled chronic obstructive pulmonary disease and asthma, restrictive lung disease, pulmonary hypertension etc. 9. Have a history of noninfectious interstitial lung disease (ILD)/pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. 10. Stroke or transient ischemic attack (TIA) within 6 months before enrollment. 11. Thromboembolic event (eg, deep vein thrombosis \[DVT\] or pulmonary embolism \[PE\]) within 6 months before enrollment except for those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before enrollment. 12. Primary tumors in the central nervous system (CNS) and active or untreated CNS metastases and/or carcinomatous meningitis should be excluded. Patients with previously treated brain metastases may participate provided they are clinically stable for at least 4 weeks and have no evidence of new or enlarging brain metastases and no requirements for corticosteroids 14 days prior to dosing with the IP. Patients on low dose corticosteroids (\<10 mg prednisone or equivalent/day) may participate. 13. Pre-existing ≥Grade 2 peripheral neuropathy. 14. Subjects who have a history of anaphylaxis or severe hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M17D1. 15. Subjects

Inclusion Criteria: * 1\. Adults \> = 18 years old. * 2\. Previous treatment with any chemotherapy because of any tumor. * 3\. Clinical diagnosis of paresthesia (numbness, tingling) secondary to CIPN, with toxicity Grade \> = 2 (according to the Common Toxicity Criteria for Adverse Events (CTCAE) from the National Cancer Institute of EEUU, v.5.0) for \> = 3 months. * 4\. Without neurotoxic chemotherapy \> = 3 months. * 5\. Cancer disease is stable or in remission. * 6\. Life expectancy \> = 6 months. * 7\. Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit and accept the use of appropriate contraceptive methods at least from 14 days before the first ozone therapy session up to 14 days after the last one. * 8\. To sign and date the study-specific informed consent Exclusion Criteria: * 1\. Age \< 18 years. * 2\. A woman who is lactating, pregnant, suspected of being pregnant, or a woman of childbearing potential who does not use adequate contraceptive methods. * 3\. Suspected symptoms are due to diabetic or compressive neuropathy. * 4\. Severe psychiatric disorders. * 5\. Inability to complete the quality of life questionnaires. * 6\. Elevation above 5 times the maximum limit of normal creatinine. * 7\. Patient who is hemodynamic or clinically unstable or who requires urgent or short-term interventional measures. * 8\. Neoplasia in progression requiring recent initiation of systemic treatment or maintenance with neurotoxic chemotherapy. * 9\. Life expectancy (for any reason) \< 6 months. * 10\. Known allergy to ozone, known glucose 6 phosphate dehydrogenase (G6PD) deficiency, or hemochromatosis. * 11\. Contraindications or impossibility for rectal ozone treatment or to attend regularly to the treatment. * 12\. Not meeting each and every one of the inclusion criteria

Inclusion Criteria: pregnant, age 18-35, possession of, or availablitiy of using a cell phone. \- Exclusion Criteria: for the control group the following are exclusion criteria: hypertension, known sleep apnea, asthma requiring daily inhaler use, other lung disease, diabetes For the group who are recruited at the time of diagnosis of pre-eclampsia - hypertension is not an exclusion criteria. \-

Inclusion Criteria: a. patients with breast cancer confirmed by histopathology, Exclusion Criteria: 1. breast implants 2. general Contraindication of MRI as claustrophobia

Inclusion Criteria: * married first-time teenage mothers aged 13-19 years attending antenatal follow-up in the selected hospitals * a single pregnancy with 28-30 weeks of gestational age * no pregnancy complications contraindicating vaginal delivery * plan to have institutional delivery and postnatal visits at the selected health hospitals and who reside for a minimum of 12 weeks postdelivery around the selected hospitals Exclusion Criteria: * have self-reported history or current mental health problems * participated in similar interventional programmes * have serious medical and obstetrics problems * having foetus with diagnosed congenital anomalies